Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study

GD Hall; JM Brown; RE Coleman; M Stead; KS Metcalf; KR Peel; Christopher Poole; M Crawford; B Hancock; PJ Selby; TJ Perren

doi:10.1038/sj.bjc.6602037

Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study

GD Hall, JM Brown, RE Coleman, M Stead, KS Metcalf, KR Peel, Christopher Poole, M Crawford, B Hancock, PJ Selby, TJ Perren

Research output: Contribution to journal › Article

76 Citations (Scopus)

Abstract

A randomised phase III trial was conducted to assess the role of interferon-alpha (INFalpha) 2a as maintenance therapy following surgery and/or chemotherapy in patients with epithelial ovarian carcinoma. Patients were randomised following initial surgery/chemotherapy to interferon-alpha 2a as 4.5 mega-units subcutaneously 3 days per week or to no further treatment. A total of 300 patients were randomised within the study between February 1990 and July 1997. No benefit for interferon maintenance was seen in terms of either overall or clinical event-free survival. We conclude that INF-alpha is not effective as a maintenance therapy in the management of women with ovarian cancer. The need for novel therapeutics or strategies to prevent the almost inevitable relapse of patients despite increasingly effective surgery and chemotherapy remains.

Original language	English
Pages (from-to)	621-626
Number of pages	6
Journal	British Journal of Cancer
Volume	91
DOIs	https://doi.org/10.1038/sj.bjc.6602037
Publication status	Published - 1 Jan 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6602037

Cite this

Hall, GD., Brown, JM., Coleman, RE., Stead, M., Metcalf, KS., Peel, KR., Poole, C., Crawford, M., Hancock, B., Selby, PJ., & Perren, TJ. (2004). Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study. British Journal of Cancer, 91, 621-626. https://doi.org/10.1038/sj.bjc.6602037

@article{87ca9bf4de6e47669c6353569ef78044,

title = "Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study",

abstract = "A randomised phase III trial was conducted to assess the role of interferon-alpha (INFalpha) 2a as maintenance therapy following surgery and/or chemotherapy in patients with epithelial ovarian carcinoma. Patients were randomised following initial surgery/chemotherapy to interferon-alpha 2a as 4.5 mega-units subcutaneously 3 days per week or to no further treatment. A total of 300 patients were randomised within the study between February 1990 and July 1997. No benefit for interferon maintenance was seen in terms of either overall or clinical event-free survival. We conclude that INF-alpha is not effective as a maintenance therapy in the management of women with ovarian cancer. The need for novel therapeutics or strategies to prevent the almost inevitable relapse of patients despite increasingly effective surgery and chemotherapy remains.",

author = "GD Hall and JM Brown and RE Coleman and M Stead and KS Metcalf and KR Peel and Christopher Poole and M Crawford and B Hancock and PJ Selby and TJ Perren",

year = "2004",

month = jan,

day = "1",

doi = "10.1038/sj.bjc.6602037",

language = "English",

volume = "91",

pages = "621--626",

journal = "British Journal of Cancer",

publisher = "Cancer Research UK",

}

Hall, GD, Brown, JM, Coleman, RE, Stead, M, Metcalf, KS, Peel, KR, Poole, C, Crawford, M, Hancock, B, Selby, PJ & Perren, TJ 2004, 'Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study', British Journal of Cancer, vol. 91, pp. 621-626. https://doi.org/10.1038/sj.bjc.6602037

TY - JOUR

T1 - Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study

AU - Hall, GD

AU - Brown, JM

AU - Coleman, RE

AU - Stead, M

AU - Metcalf, KS

AU - Peel, KR

AU - Poole, Christopher

AU - Crawford, M

AU - Hancock, B

AU - Selby, PJ

AU - Perren, TJ

PY - 2004/1/1

Y1 - 2004/1/1

N2 - A randomised phase III trial was conducted to assess the role of interferon-alpha (INFalpha) 2a as maintenance therapy following surgery and/or chemotherapy in patients with epithelial ovarian carcinoma. Patients were randomised following initial surgery/chemotherapy to interferon-alpha 2a as 4.5 mega-units subcutaneously 3 days per week or to no further treatment. A total of 300 patients were randomised within the study between February 1990 and July 1997. No benefit for interferon maintenance was seen in terms of either overall or clinical event-free survival. We conclude that INF-alpha is not effective as a maintenance therapy in the management of women with ovarian cancer. The need for novel therapeutics or strategies to prevent the almost inevitable relapse of patients despite increasingly effective surgery and chemotherapy remains.

AB - A randomised phase III trial was conducted to assess the role of interferon-alpha (INFalpha) 2a as maintenance therapy following surgery and/or chemotherapy in patients with epithelial ovarian carcinoma. Patients were randomised following initial surgery/chemotherapy to interferon-alpha 2a as 4.5 mega-units subcutaneously 3 days per week or to no further treatment. A total of 300 patients were randomised within the study between February 1990 and July 1997. No benefit for interferon maintenance was seen in terms of either overall or clinical event-free survival. We conclude that INF-alpha is not effective as a maintenance therapy in the management of women with ovarian cancer. The need for novel therapeutics or strategies to prevent the almost inevitable relapse of patients despite increasingly effective surgery and chemotherapy remains.

UR - http://www.scopus.com/inward/record.url?scp=4344703324&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602037

DO - 10.1038/sj.bjc.6602037

M3 - Article

C2 - 15305182

VL - 91

SP - 621

EP - 626

JO - British Journal of Cancer

JF - British Journal of Cancer

ER -

Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this